

Deepak Parashar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4819441/publications.pdf>

Version: 2024-02-01

34
papers

703
citations

471509

17
h-index

580821

25
g-index

36
all docs

36
docs citations

36
times ranked

844
citing authors

#	ARTICLE	IF	CITATIONS
1	Using Omics to Study Leprosy, Tuberculosis, and Other Mycobacterial Diseases. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 792617.	3.9	7
2	Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. <i>Cancers</i> , 2022, 14, 958.	3.7	13
3	Tumor Derived Extracellular Vesicles Drive T Cell Exhaustion in Tumor Microenvironment through Sphingosine Mediated Signaling and Impacting Immunotherapy Outcomes in Ovarian Cancer. <i>Advanced Science</i> , 2022, 9, e2104452.	11.2	20
4	Emerging Roles and Potential Applications of Non-Coding RNAs in Cervical Cancer. <i>Genes</i> , 2022, 13, 1254.	2.4	6
5	Genomic analysis of a novel species <i>Halomonas shambharensis</i> isolated from hypersaline lake in Northwest India. <i>Molecular Biology Reports</i> , 2021, 48, 1045-1053.	2.3	1
6	Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance. <i>Npj Precision Oncology</i> , 2021, 5, 16.	5.4	13
7	Therapeutic management of <i>Mycobacterium avium</i> subspecies paratuberculosis infection with complete resolution of symptoms and disease in a patient with advanced inflammatory bowel syndrome. <i>Molecular Biology Reports</i> , 2021, 48, 7013-7020.	2.3	4
8	Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth. <i>Cancer Research</i> , 2021, 81, 5336-5352.	0.9	27
9	RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site. <i>Cell Reports</i> , 2021, 37, 109934.	6.4	34
10	Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling. <i>Cancer Research</i> , 2020, 80, 5554-5568.	0.9	29
11	scFv6.C4 DNA vaccine with fragment C of tetanus toxin increases protective immunity against CEA-expressing tumor. <i>Gene Therapy</i> , 2020, 28, 287-289.	4.5	2
12	ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis. <i>Oncogene</i> , 2020, 39, 2921-2933.	5.9	28
13	Whole-Genome Shotgun Sequence of <i>Halomonas</i> sp. Strain SBS 10, Isolated from a Hypersaline Lake in India. <i>Microbiology Resource Announcements</i> , 2020, 9, .	0.6	4
14	Cell Cycle Arrest: An Impending Therapeutic Strategy to Curb Cancer. , 2020, , 45-63.		1
15	Metastasis: A Major Driver of Cancer Pathogenesis. , 2020, , 185-211.		0
16	Betaine accumulation suppresses the de-novo synthesis of ectoine at a low osmotic concentration in <i>Halomonas</i> sp SBS 10, a bacterium with broad salinity tolerance. <i>Molecular Biology Reports</i> , 2019, 46, 4779-4786.	2.3	26
17	Multiplex PCR assay for simultaneous detection and differentiation of <i>Entamoeba histolytica</i> , <i>Giardia lamblia</i> , and <i>Salmonella</i> spp. in the municipality-supplied drinking water. <i>Journal of Laboratory Physicians</i> , 2019, 11, 275-280.	1.1	5
18	miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2019, 29, 4389-4406.e10.	6.4	55

#	ARTICLE	IF	CITATIONS
19	ERBB signaling in CTCs of ovarian cancer and glioblastoma. <i>Genes and Cancer</i> , 2017, 8, 746-751.	1.9	16
20	Sperm-associated antigen 9 (SPAG9) promotes the survival and tumor growth of triple-negative breast cancer cells. <i>Tumor Biology</i> , 2016, 37, 13101-13110.	1.8	19
21	Heat shock protein 70 (HSP70-2) is a novel therapeutic target for colorectal cancer and is associated with tumor growth. <i>BMC Cancer</i> , 2016, 16, 561.	2.6	50
22	A novel cancer testis antigen target A-kinase anchor protein (AKAP4) for the early diagnosis and immunotherapy of colon cancer. <i>Oncolmmunology</i> , 2016, 5, e1078965.	4.6	20
23	A-kinase anchor protein 4 (AKAP4) a promising therapeutic target of colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 142.	8.6	40
24	Sperm associated antigen 9 (SPAG9) expression and humoral response in benign and malignant salivary gland tumors. <i>Oncolmmunology</i> , 2014, 3, e974382.	4.6	8
25	Effect of micronutrient supplementation on treatment outcomes in children with intrathoracic tuberculosis: a randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2014, 100, 1287-1297.	4.7	23
26	Gene silencing of A-kinase anchor protein 4 inhibits cervical cancer growth in vitro and in vivo. <i>Cancer Gene Therapy</i> , 2013, 20, 413-420.	4.6	23
27	Down regulation of SPAG9 reduces growth and invasive potential of triple-negative breast cancer cells: possible implications in targeted therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 69.	8.6	38
28	Usefulness of multiplex PCR in the diagnosis of genital tuberculosis in females with infertility. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 399-405.	2.9	18
29	Does Neutralization of Gastric Aspirates from Children with Suspected Intrathoracic Tuberculosis Affect Mycobacterial Yields on MGIT Culture?. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1753-1756.	3.9	23
30	The novel cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target for immunotherapy of ovarian serous carcinoma. <i>Oncolmmunology</i> , 2013, 2, e24270.	4.6	35
31	Expression and Humoral Response of A-Kinase Anchor Protein 4 in Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 650-658.	2.5	22
32	Sperm Associated Antigen 9 Plays an Important Role in Bladder Transitional Cell Carcinoma. <i>PLoS ONE</i> , 2013, 8, e81348.	2.5	32
33	Cancer testis antigens. <i>Oncolmmunology</i> , 2012, 1, 1194-1196.	4.6	39
34	Recovery of <i>Mycobacterium tuberculosis</i> from Sputum Treated with Cetyl Pyridinium Chloride. <i>Journal of Clinical Microbiology</i> , 2009, 47, 4189-4190.	3.9	16